Molecular targeted therapy of triple-negative breast cancer

Abstract

Abstract:Treatment options are limited for triple negative breast cancer (TNBC) since endocrinotherapy and targeted therapy that aims directly at human epidermal growth factor receptor-2 (HER-2) are ineffective. As such, in addition to surgical treatment, the mainstay of treatment of TNBC is systemic cytotoxic chemotherapy. The targeted therapy of TNBC is becoming a research hotspot because of traditional chemotherapy curative effect is not good enough. A large number of clinical trials have found that patients with TNBC can get benefits from targeted molecular strategies including polyadenosine diphosphate glucose pyrophospheralase-ribose polymerase-1 (PARP-1) inhibitor and epidermal growth factor receptor (EGFR) inhibitor.

Key words:Breast neoplasms,Antineoplastic agents,Molecular targeted therapy

Gong Liya, Chen Hongfeng. Molecular targeted therapy of triple-negative breast cancer[J]. Journal of International Oncology, 2014, 41(8): 662-665.

References

［1］ Loesch D, Asmar L, McIntyre K, et al. Phase Ⅱ trial of gemcitabine/carboplatin (plus trastuzumab in HER2positive disease) in patients with metastatic breast cancer［J］. Clin Breast Cancer, 2008, 8(2): 178-186. ［2］ Yardley DA, Burris HA 3rd, Simons L, et al. A phase Ⅱ trial of gemcitabine/carboplatin with or without trastuzumab in the firstline treatment of patients with metastatic breast cancer［J］. Clin Breast Cancer, 2008, 8(5): 425-431. ［3］ Chew HK, Doroshow JH, Frankel P, et al. Phase Ⅱ studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer［J］. J Clin Oncol, 2009, 27(13): 2163-2169. ［4］ Ossovskaya V, Li L, Broude EV, et al. BSI201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer(Abstract 5552)(C/OL). Proceedings of the 2009 AmericanAssociation for Cancer Research 100th Annual Meeting, Denver,Co, 2009. ［5］ Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triplenegative breast cancer cell lines to poly(ADPRibose) polymerase inhibition, gemcitabine, and cisplatin［J］. Cancer Res, 2010, 70(20): 7970-7980. ［6］ O′Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triplenegative breast cancer［J］. N Engl J Med, 2011, 364(3): 205-214. ［7］ O′Shaughnessy J,Schwartzberg LS，Danso MA，et al. A randomized phase Ⅲ study of iniparib (BSI201) in combination with gemcitabine/carboplatin(G/C) in metastatic triplenegative breast cancer(mTNBC)［J］. J Clin Oncol, 2011, 29(Suppl): abstract 1007. ［8］ Miles DW, Diéras V, Cortés J, et al. Firstline bevacizumab in combination with chemotherapy for HER2negative metastatic breast cancer:pooled and subgroup analyses of data from 2447 patients［J］. Ann Oncol, 2013, 24(11): 2773-2780. ［9］ Thomssen C, Pierga JY, Pritchard KI, et al. Firstline bevacizumabcontaining therapy for triplenegative breast cancer: analysis of 585 patients treated in the ATHENA study［J］. Oncology, 2012, 82(4): 218-227. ［10］ Dank M, Budi L, Piko B, et al. Firstline bevacizumabpaclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study［J］. Anticancer Res, 2014, 34(3): 1275-1280. ［11］ Brufsky AM, Hurvitz S, Perez E, et al. RIBBON2:a randomized, doubleblind, placebocontrolled, phase Ⅲ trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for secondline treatment of human epidermal growth factor receptor 2negative metastatic breast cancer［J］. J Clin Oncol, 2011, 29(32): 4286-4293. ［12］ Brufsky AM, Valero V, Tiangco B, et al. Secondline bevacizumabcontaining therapy in patients with triplenegative breast cancer: subgroup analysis of the RIBBON2 trial［J］. Breast Cancer Res Treat, 2012, 133(3): 1067-1075. ［13］ von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2negative breast cancer［J］. N Engl J Med, 2012, 366(4): 299-309. ［14］ Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer［J］. N Engl J Med, 2007, 357(26): 2666-2676. ［15］ Robert NJ, Diéras V, Glaspy J, et al. RIBBON1:randomized, doubleblind, placebocontrolled, phase Ⅲ trial of chemotherapy with or without bevacizumab for firstline treatment of human epidermal growth factor receptor 2negative, locally recurrent or metastatic breast cancer［J］. J Clin Oncol, 2011, 29(10): 1252-1260. ［16］ Miles DW, Chan A, Dirix LY, et al. Phase Ⅲ study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the firstline treatment of human epidermal growth factor receptor 2negative metastatic breast cancer［J］. J Clin Oncol, 2010, 28(20): 3239-3247. ［17］ O′Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracyclinepretreated patients with advanced breast cancer: phase Ⅲ trial results［J］. J Clin Oncol, 2002, 20(12): 2812-2823. ［18］ Albain KS, Nag SM, CalderilloRuiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment［J］. J Clin Oncol, 2008, 26(4): 3950-3957. ［19］ Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer［J］. N Engl J Med, 2012, 366(4): 310-320. ［20］ Burstein HJ, Elias AD, Rugo HS, et al. Phase Ⅱ study of sunitinib malate,an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane［J］. J Clin Oncol, 2008, 26(11): 1810-1816. ［21］ Barrios CH, Liu MC, Lee SC, et al. Phase andomized trial of sunitinib versus capecitabine in patients with previously treated HER2negative advanced breast cancer［J］. Breast Cancer Res Treat, 2010, 121(1): 121-131. ［22］ Bergh J, Bondarenko IM, Lichinitser MR, et al. Firstline treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase Ⅲ study［J］. J Clin Oncol, 2012, 30(9): 921-929. ［23］ Crown JP, Diéras V, Staroslawska E, et al. Phase Ⅲ trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer［J］. J Clin Oncol, 2013, 31(23): 2870-2878. ［24］ Gradishar WJ, Kaklamani V, Sahoo TP, et al. A doubleblind,randomised, placebocontrolled, phase 2b study evaluating sorafenib in combination with paclitaxel as a firstline therapy in patients with HER2negative advanced breast cancer［J］. Eur J Cancer, 2013, 49(2): 312-322. ［25］ Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triplenegative breast cancer: distinguishing between basal and nonbasal subtypes［J］. Clin Cancer Res, 2009, 15(7): 2302-2310. ［26］ Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triplenegative breast cancer［J］. Ann Oncol, 2009, 20(5): 862-867. ［27］ Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001:randomized phase Ⅱ study of cetuximab in combination with carboplatin in stage Ⅳ triplenegative breast cancer［J］. J Clin Oncol, 2012, 30(21): 2615-2623. ［28］ O′Shaughnessy J, Weckstein DJ, Vukelja SJ, et al. Preliminary results of a randomized phase Ⅱ study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer［J］. Breast Cancer Res Treat, 2007, 106 Suppl 1: S32. ［29］ Baselga J, Gómez P, Greil R, et al. Randomized phase Ⅱ study of the antiepidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triplenegative breast cancer［J］. J Clin Oncol, 2013, 31(20): 2586-2592. ［30］ Bernsdorf M, Ingvar C, Jrgensen L, et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase Ⅱ trial［J］. Breast Cancer Res Treat, 2011, 126(2): 463-470.

[1]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[2]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[4]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[5]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[6]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[7]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[8]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[9]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[10]	Huang Hui, Ding Jianghua.Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma[J]. Journal of International Oncology, 2023, 50(9): 569-573.
[11]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[12]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[13]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[14]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[15]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong.Progress of PARP inhibitors in targeted therapy of small cell lung cancer[J]. Journal of International Oncology, 2023, 50(6): 368-372.